Literature DB >> 11455860

New therapies in development for autoimmune diseases: their rationale for combination treatment.

V Strand1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11455860     DOI： 10.1007/s002810100071

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


× No keyword cloud information.
  80 in total

1.  The CD40 ligand expressed by human B cells costimulates B cell responses.

Authors:  A C Grammer; M C Bergman; Y Miura; K Fujita; L S Davis; P E Lipsky
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

Review 2.  Gene therapy for rheumatic diseases.

Authors:  C H Evans; S C Ghivizzani; R Kang; T Muzzonigro; M C Wasko; J H Herndon; P D Robbins
Journal:  Arthritis Rheum       Date:  1999-01

3.  Adenoviral vector-mediated overexpression of IL-4 in the knee joint of mice with collagen-induced arthritis prevents cartilage destruction.

Authors:  E Lubberts; L A Joosten; L van Den Bersselaar; M M Helsen; A C Bakker; J B van Meurs; F L Graham; C D Richards; W B van Den Berg
Journal:  J Immunol       Date:  1999-10-15       Impact factor: 5.422

Review 4.  Immunoregulatory circuits and potential treatment of connective tissue diseases.

Authors:  J Alcocer-Varela; L Llorente; D Alarcón-Segovia
Journal:  Int Arch Allergy Immunol       Date:  1996-12       Impact factor: 2.749

5.  Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera.

Authors:  P H Wooley; H S Luthra; W P Lafuse; A Huse; J M Stuart; C S David
Journal:  J Immunol       Date:  1985-04       Impact factor: 5.422

6.  Evidence for the effects of a superantigen in rheumatoid arthritis.

Authors:  X Paliard; S G West; J A Lafferty; J R Clements; J W Kappler; P Marrack; B L Kotzin
Journal:  Science       Date:  1991-07-19       Impact factor: 47.728

7.  The type I interleukin-1 receptor acts in series with tumor necrosis factor (TNF) to induce arthritis in TNF-transgenic mice.

Authors:  L Probert; D Plows; G Kontogeorgos; G Kollias
Journal:  Eur J Immunol       Date:  1995-06       Impact factor: 5.532

8.  Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10.

Authors:  P Chomarat; E Vannier; J Dechanet; M C Rissoan; J Banchereau; C A Dinarello; P Miossec
Journal:  J Immunol       Date:  1995-02-01       Impact factor: 5.422

9.  Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1.

Authors:  A F Kavanaugh; L S Davis; L A Nichols; S H Norris; R Rothlein; L A Scharschmidt; P E Lipsky
Journal:  Arthritis Rheum       Date:  1994-07

10.  T cell receptor peptide vaccination in rheumatoid arthritis: a placebo-controlled trial using a combination of Vbeta3, Vbeta14, and Vbeta17 peptides.

Authors:  L W Moreland; E E Morgan; T C Adamson; Z Fronek; L H Calabrese; J M Cash; J A Markenson; A K Matsumoto; J Bathon; E L Matteson; K M Uramoto; C M Weyand; W J Koopman; L W Heck; V Strand; J P Diveley; D J Carlo; C J Nardo; S P Richieri; S W Brostoff
Journal:  Arthritis Rheum       Date:  1998-11
View more
  2 in total

1.  Immunosuppression by co-stimulatory molecules: inhibition of CD2-CD48/CD58 interaction by peptides from CD2 to suppress progression of collagen-induced arthritis in mice.

Authors:  Ameya Gokhale; Shanthi Kanthala; John Latendresse; Veena Taneja; Seetharama Satyanarayanajois
Journal:  Chem Biol Drug Des       Date:  2013-07       Impact factor: 2.817

Review 2.  Autoimmune disorders: a concept of treatment based on mechanisms of disease.

Authors:  Peter A Miescher; Laura Zavota; Alejandra Ossandon; Bruno Lagana
Journal:  Springer Semin Immunopathol       Date:  2003-11-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.